Mecsense AS located at Oslo Innovation Centre is developing a continuous and non-invasive glucose indicator for diabetics based on a newly discovered principle for density and viscosity measurements in cooperation with Mid Sweden University, Emzense AB and ShortLink AB in Sweden and Noliac AS in Denmark. The density of the body liquids and viscosity caused by variations of the glucose level are measured by a novel physical principle protected by two patent applications.
The principle has been verified in controlled environment conditions in laboratory and in-house pilot studies on humans with a deviation from blood taken readings of less than 15%.
The aim of Mecsense now is to build a limited number of sensors for clinical trials at well perpetuated hospitals in Scandinavia.
In Q4 2016 and Q1 2017 PZT elements with different frequencies have been optimized by tests in sugar solutions and the optimal frequency have been found. In addition a new method of application to the body was found which improved the sensitivity of the sensors. This has been followed up by tests on 2 diabetics with promissing results. As a result of these tests and analysis of the performance, a new type of PZT with the same frequency has been recommended.
The first sensors are expected to be available at the end of 2018.
This is a project supported by NFR, Oslo MedTech and Innovation Norway and Skatte-Funn.